
BIOGRAPHICAL SKETCH

NAME: Jeffrey B Reich, MD

POSITION TITLE: CEO, Sparian Biosciences

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Binghamton University	BA	June / 1983	Biology
Weill Cornell Medical School, Cornell University	MD	June 1987	Medicine
NYU / Bellevue	Intern	June 1988	Medicine
New York Hospital / Weill Cornell	Resident/ Fellow	June 1993	Neurology

A. Personal Statement

I have over 30 years of experience in science, medicine, finance and drug development. As CEO of Sparian, I am leading the development of a novel, safe analgesic through CMC, tox and a phase 1 clinical trial and I have lead the development of the SBS-226 program to date. I am PI on a UH3 grant for the novel analgesic and was PI on a Phase 1 SBIR for SBS-226 and a UG3 grant for SBS-518 for Stimulant Use Disorder. I am a neurologist by training and those early years helped me build a strong foundation of knowledge in the neurobiology of pain, opioids, OUD, and other substance use disorders. As an Attending Neurologist and Assistant Professor of Neurology at Cornell, I established and built the Cornell Headache Center. In under 10 years the program was thriving. I had funding to support a fellow, and a full time clinical research associate. We were treating upwards of 80 patients per week both inpatient and outpatient. I was doing clinical trials for the large pharmaceutical companies including Merck, Pfizer, Pharmacia, Novartis and Elan. Cornell was the first headache center to propose and initiate pilot trials of botulinum toxin for chronic headache.

After participating as a primary investigator on several clinical trials for pharma, I became more interested in the business of drug development than the practice. In 2001, I left clinical medicine for finance. For 17 years I worked for two asset management funds focusing on both early and commercial stage companies. I managed an investment portfolio worth between \$1B – \$1.5B devoted to investing in innovative therapeutics. As an analyst and portfolio manager at Merlin Bio Med, we took active positions in early stage enterprises. In 2005 I became a founding board member of Neurologix – a gene therapy company focusing on disorders of the nervous system. Neurologix was without a functioning CEO and as the only board member with a medical background, I assumed many of the duties of a fulltime CEO. I worked closely with the clinical and regulatory team to secure an IND that led to a successful phase 2a trial of AAV2/ GAD in Parkinson's Disease (Lancet Neurology April 2011). In addition I led the board effort in seeking a strategic partnership culminating in a term sheet from a major multinational pharmaceutical company. I also successfully negotiated our series C and series D financing.

For the past 5 years I have served on the selection committee of the Roberston Fund at Rockefeller University. ***This is a voluntary position with no compensation.*** Our mission has been to identify and help shepherd programs with promising translational value through development and into the clinic. While I have seen many interesting proposals, some with great potential, few have been as compelling as a novel treatment for OUD in today's substance use disorder crisis. I can deliver the clear thinking and unfettered leadership required to

bring this drug through successful development. This experience directly supports my ability to execute on this project and collaborate with the industry partners and advisors I am already working with.

B. Positions and Honors

2019 – present	Sparian Biosciences, CEO and Co-founder
2007 – 2019	CRM Funds, portfolio manager Life Sciences/ Healthcare
2001 – 2007	Merlin Bio Med, Analyst / Portfolio Manager
2015- 2020	Rockefeller University Roberston Fund, Selection Committee
2005 – 2012	Neurologix, Director
2007 - 2012	Scolr Pharma, Director
1994 – 2005	Weill Medical College of Cornell University, Assistant Professor Neurology
1994 – 2005	New York Presbyterian Hospital, Attending Physician
1988	Robert F. Pitts Prize Weill College Medicine, Cornell for outstanding research by a medical student
1987	Alpha Omega Alpha Medical Honor Society
1987	Paul Sherlock Prize for outstanding performance as a medical student in clinical medicine
1986	Harold G Wolff Award Weill Colege of Medicine, Cornell for outstanding research in neuroscience

EDITORIAL POSITIONS

1997- 2005	Neurology Alert Thompson American Health Consultants, Publisher Atlanta, GA
-------------------	---

C. CONTRIBUTION TO SCIENCE

In Dr Bernice Grafstein's lab we studied nerve regeneration in using the goldfish optic nerve as a model. I helped develop the conditioned lesion paradigm and helped characterize the cellular mechanisms of response to nerve injury.

Effects of conditioning lesions on regeneration of goldfish optic axons; time course of the cell body reaction to axotomy Reich JB, Burmeister DW, Schmidt JT, Grafstein B. Brain Research 515 (1-2): 256-60 1990. PMID: 2357564

Some of the foundational concepts in clinical neurology are based upon the relationships between structure and function. In particular the integrity of the brain during certain pathologic conditions is vital to maintaining arousal and consciousness. We were the first group to use MRI to demonstrate and correlate structural changes to states of consciousness.

Magnetic resonance imaging measurements and clinical changes accompanying transtentorial and foramen magnum brain herniation. Reich JB, Sierra J, Camp w, Zanzonio P, Deck MD, Plum F. Annals of Neurology 33: 159-170 1993. PMID843877.

MRI changes in intracranial hypotension Pannullo SC, Reich JB, Krol G, Deck MDF, Posner JB *Neurology* 43: 919-926 1993 *Headache Disorders* Reich JB, Merck Manual 1999 edition. PMID: 8492946

D. GRANT AND RESEARCH SUPPORT

2021: Arylepoxamides: A new class of potent, safer analgesics. NIDA Grant UH3DA048379. Primary Investigator.

2021: Development of CP-analogs as novel treatments for opioid use disorder. NIDA Grant R44DA053846. Primary Investigator.

- 1998 Stress, Anxiety and Migraine; a prospective, population based study looking at migraine and co morbid variables. Merck-Cornell Research Grant 12/1/1999; primary investigator
- 1999 Fear of Triptans; a clinician and patient directed survey to analyze prescription practices and compliance issues with the triptan migraine drugs. Merck-Cornell Research Grant 12/1/1999.; primary investigator
- 1999 Almotriptan (LAS31416) vs. sumatriptan in a double blind, randomized, parallel group, multicenter study of cost effectiveness and quality of life in migraine, Pharmacia & Upjohn 1999; primary investigator.
- 1997 A mulitcenter CABG study investigating aortic atheroma and emboli in relation to neurologic outcome. NIH supported grant 2RO1 HL 44719-04A1. Mary Charlson, M.D. primary investigator.
- 1997 A multicenter, double-blind, randomized, placebo-controlled, parallel group study of the efficacy and safety of oral eletriptan in adolescent subjects aged 12 to 17 years with acute migraine, Pfizer 1997; Syed Hosain, M.D. Co-primary investigator
- 1997 A multicenter, randomized, open-label, comparative study of the efficacy, safety and toleration of oral eletriptan for long-term treatment of subjects with acute migraine. Pfizer 1997; Syed Hosain, M.D. Co-primary investigator